MISSISSAUGA, ON, April 30, 2013 /CNW/ - Amgen, a biotechnology company
developing both innovative biologic and biosimilar medicines, welcomes
a new report from the European Commission detailing Europe's strong regulatory and
commercial foundation for biosimilars in the healthcare marketplace.
The report shows that biosimilars are helping improve competition and
thus may be increasing access to biologic medicines for patients.
The science-led regulatory framework in the European Union (EU) has
established confidence in biosimilars which has allowed for these
therapeutic alternatives to successfully enter into clinical practice.
As governments, industry and the healthcare sector work together to
improve health outcomes, the report reaffirms that protecting patient
safety is the cornerstone of the EU's regulatory framework for
Amgen, a core stakeholder in the consultation process for this report,
welcomes the opportunity this consensus document provides for ongoing
balanced and informed discussions on the European biosimilars
experience. This report is designed to help national governments,
health care professionals and patients make informed choices on the
role current and future biosimilar medicines may have in achieving
optimal healthcare outcomes.
SOURCE Amgen Canada